ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Teixeira MM, Theodoro RC, Carvalho MJA, Fernandes L, Paes HC, Hahn RC, Mendoza L, Bagagli E, San-Blas G, Felipe MSS, 2009. Phylogenetic analysis reveals a high level of speciation in the Paracoccidioides genus. Mol Phylogenet Evol 52: 273–283.
-
2.
Hahn RC, Rodrigues AM, Fontes CJ, Nery AF, Tadano T, Queiroz L de P Jr, de Camargo ZP, 2014. Fatal fungemia due to Paracoccidioides lutzii. Am J Trop Med Hyg 91: 394–398.
-
3.
Teixeira MM, Theodoro RC, Oliveira FF, Machado GC, Hahn RC, Bagagli E, San-Blas G, Soares FMS, 2014. Paracoccidioides lutzii sp. nov.: biological and clinical implications. Med Mycol 52: 19–28.
-
4.
Giraldo R, Restrepo A, Gutierrez F, Robledo M, Londono F, Hernandez H, Sierra F, Calle G, 1976. Pathogenesis of paracoccidioidomycosis: a model based on the study of 46 patients. Mycopathologia 58: 63–70.
-
5.
Franco M, Montenegro MR, Mendes RP, Marques SA, Dillon ML, Mota NGS, 1987. Paracoccidioidomycosis: a recently proposed classification of its clinical forms. Rev Soc Bras Med Trop 20: 129–132.
-
6.
Coutinho ZF, Silva D, Lazera M, Petri V, Oliveira RM, Sabroza PC, Wanke B, 2002. Paracoccidioidomycosis mortality in Brazil (1980–1995). Cad Saude Publica 18: 1441–1454.
-
7.
Lacaz CS, Porto E, Martins JEC, Heins-Vaccari EM, Melo NT, 2002. Paracoccidioidomicose. Lacaz CS, Porto E, Martins JEC, Heins-Vaccari EM, Melo NT, eds. Tratado de Micologia Medica. Lacaz, 9th edition. São Paulo, Brazil: Servier, 639–729.
-
8.
Shikanai-Yasuda MA, Queiroz-Telles Filho F, Mendes RP, Colombo AL, Moretti ML, Guidelines in Paracoccidioidomycosis Consulting Group, 2006. Guidelines in paracoccidioidomycosis. Rev Soc Bras Med Trop 39: 297–310.
-
9.
Kalmar EMN, Alencar FEC, Alves FP, Pang LW, Del Negro GMB, Camargo ZP, Shikanai-Yasuda MA, 2004. Paracoccidioidomycosis: an epidemiologic survey in a pediatric population from the Brazilian Amazon using skin tests. Am J Trop Med Hyg 71: 82–86.
-
10.
Martinez R, Moya MJ, 1992. The relationship between paracoccidioidomycosis and alcoholism. Rev Saude Publica 26: 12–16.
-
11.
Santos WA, da Silva BM, Passos ED, Zandonadi E, Falqueto A, 2003. Association between smoking and paracoccidioidomycosis, a case-control study and state of Espírito Santo, Brasil. Cad Saude Publica 19: 245–253.
-
12.
Queiroz-Telles, 2009. Terapêutica. Veronesi R, Foccacia R, eds. Tratado de Infectologia, 4th edition. São Paulo, Brazil: Atheneu, 1539–1545.
-
13.
Campos MVS, Penna GO, Castro CN, Moraes MAP, Ferreira MS, Santos JB, 2008. Paracoccidioidomycosis at Brasília’s University Hospital. Rev Soc Bras Med Trop 41: 169–172.
-
14.
Menezes VM, Soares BGO, Fontes CJF, 2006. Drugs for treating paracoccidioidomycosis. Cochrane Database Syst Rev 19: CD004967.
-
15.
Shikanai-Yasuda MA, Benard G, Higaki Y, Del Negro GMB, Hoo S, Vaccari EH, Gryschek RCB, Segurado AAC, Barone AA, Andrade DR, 2002. Randomized trial with itraconazole, ketoconazole and sulfadiazine in paracoccidioidomycosis. Med Mycol 40: 411–417.
-
16.
Borges SR, Silva GM, Chambela M da C, Oliveira R de V, Costa RL, Wanke B, Valle AC, 2014. Itraconazole vs. trimethoprim-sulfamethoxazole: a comparative cohort study of 200 patients with paracoccidioidomycosis. Med Mycol 52: 303–310.
-
17.
Cavalcante RS, Sylvestre TF, Levorato AD, Carvalho LR, Mendes RP, 2014. Comparison between itraconazole and cotrimoxazole in the treatment of paracoccidioidomycosis. PLoS Negl Trop Dis 8: 1–11.
-
18.
Fiol FS, Oliveira S de J, Barberato-Filho S, Junqueira FM, Rocha MC, Toledo MI, 2013. Paracoccidioidomycosis: evaluation of treatment and patient profile. Braz J Infect Dis 17: 720–721.
-
19.
Marques SA, 2003. Paracoccidioidomycosis: epidemiological, clinical and treatment update. An Bras Dermatol 78: 135–150.
-
20.
Barraviera B, Mendes RP, Machado JM, Pereira PCM, Souza MJ, Meira DA, 1989. Evaluation of treatment of paracoccidioidomycosis with cotrimazine (combination of sulfadiazine and trimetoprim). Preliminary report. Rev Inst Med Trop Sao Paulo 31: 53–55.
-
21.
Barbosa W, Vasconcelos WMP, 1973. Effects of an association of sulfamethoxazole an trimethoprim in the treatment of the South American blastomycosis. Rev Pat Trop 2: 329–339.
-
22.
Valle ACF, Wanke B, Wanke NCF, Lima NS, Perez M, 1993. Treatment of paracoccidioidomycosis; retrospective: retrospective study of 500 cases. II—evaluation of therapeutic results with sulfonamides, amphotericin B, ketoconazole and miconazole. An Bras Dermatol 68: 65–70.
-
23.
Mendes RP, Meira DA, Marcondes-Machado J, Pereira TCM, Barraviera B, 1996. Sulfamethoxazole-trimethoprim combination (CMX) in the treatment of paracoccidioidomycosis (PBM). Rev Soc Bras Med Trop 29: 112.
-
24.
Marques SA, 2013. Paracoccidioidomycosis: epidemiological, clinical, diagnostic and treatment up-dating. An Bras Dermatol 88: 700–711.
-
25.
Sylvestre TF, Franciscone-Silva LR, Cavalcante RS, Moris DV, Venturini J, Vicentini AP, Carvalho LR, Mendes RP, 2014. Prevalence and serological diagnosis of relapse in paracoccidioidomycosis patients. PLoS Negl Trop Dis 8: e2834.
-
26.
Peçanha PM, 2012. Epidemiological and clinical aspects of paracoccidioidomycosis in Espírito Santo state, Brazil, MD thesis. Vitória, Brazil: Federal University of Espírito Santo. Available at: http://portais4.ufes.br/posgrad/teses/tese_5888_.pdf. Accessed April 30, 2017.
-
27.
Marques SA, 1998. Paracoccidioidomycosis: treatment with itraconazole: obtained results after an extended follow-up, PHD thesis. Botucatu, Brazil: Statal University of São Paulo. Available at: http://bases.bireme.br/cgi-bin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&src=google&base=LILACS&lang=p&nextAction=lnk&exprSearch=270241&indexSearch=ID. Acessed April 30, 2017.
-
28.
Marques SA, Shikanai-Yasuda MA, 1993. Paracoccidioidomycosis associated with immunosuppression, AIDS, and cancer. Franco M, Lacaz CS, Restrepo-Moreno A, Del Negro G, eds. Paracoccidioidomycosis. Boca Raton, FL: CRC Press, 393–405.
-
29.
Pedro RJ, Aoki FH, Boccato RSB, Branchini MLM, Gonçalves FL Junior, Papaiordanou PMO, Ramos MC, 1989. Paracoccidioidomycosis and human immunodeficiency virus infection. Rev Inst Med Trop Sao Paulo 31: 119–125.
-
30.
Benard G, Duarte AJS, 2000. Paracoccidioidomycosis: a model for evaluation of the effects of human immunodeficiency virus infection on the natural history of endemic tropical diseases. Clin Infect Dis 31: 1032–1039.
-
31.
Valle ACF, Wanke B, Wanke NCF, Peixoto TC, Perez M, 1992. Treatment of paracoccidioidomycosis: retrospective study of 500 cases. An Bras Dermatol 67: 251–254.
-
32.
Paniago AMM, Aguiar JIA, Aguiar ES, Cunha RV, Pereira GROL, Londero AT, Wanke B, 2003. Paracoccidioidomycosis: a clinical and epidemiological study of 422 cases observed in Mato Grosso do Sul. Rev Soc Bras Med Trop 36: 455–459.
-
33.
Maciel MHV, 2007. Adhesion of patients with paracoccidioidomycosis cutaneous mucosa attended in a school hospital situated in the interior of São Paulo State, MD thesis. Ribeirão Preto, Brazil: University of São Paulo.
-
34.
Batista J Jr, Camargo ZP, Fernandes GF, Vicentini AP, Fontes CJF, Hahn RC, 2010. Is the geographical origin of a Paracoccidioides brasiliensis isolate important for antigen production for regional diagnosis of paracoccidioidomycosis? Mycoses 53: 176–180.
-
35.
Vieira GD, Alves TC, Sousa CM, 2012. Epidemiological analysis of AIDS in elderly in the state of Rondonia, Western Amazon. J Bras Doenças Sex Transm 24: 49–52.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 0 | 0 | 0 |
| Full Text Views | 330 | 126 | 2 |
| PDF Downloads | 75 | 24 | 2 |
Therapeutic Response in Adult Patients with Nonsevere Chronic Paracoccidioidomycosis Treated with Sulfamethoxazole–Trimethoprim: A Retrospective Study
According to the Brazilian Consensus on Paracoccidioidomycosis (PCM), itraconazole is the drug of choice for treatment. However, the combination of sulfamethoxazole and trimethoprim (SMX-TMP) is most commonly used in clinical practice because of its higher availability in the public health services. The aims of this study were to evaluate the therapeutic response of patients with nonsevere chronic PCM to SMX-TMP and highlight the factors related to treatment failure. An adequate therapeutic response was defined as completely improved disease signs and symptoms after medication use for a minimum of 6 months, followed by normalized hematological and biochemical changes, radiological improvements, and negative mycological examination findings. Medical records were analyzed for 244 patients with nonsevere chronic PCM who were treated between 1998 and 2014. In total, 41.9% of the patients had PCM for ≥ 8 months. Seven (2.9%) patients were coinfected with human immunodeficiency virus (HIV). The median (25%, 75% percentiles) treatment duration was 21 (10, 25) months. Adequate treatment adherence was reported by 68.3% of patients. In addition, 73.6% of patients exhibited an adequate therapeutic response. The majority (82.6%) of patients who were treated with SMX-TMP for > 24 months displayed an adequate therapeutic response, and the frequency of adequate therapeutic response gradually decreased as the duration of treatment decreased. Treatment nonadherence (P < 0.001) and PCM-HIV coinfection (P = 0.019) were factors associated with therapeutic failure. The study results support the good efficacy of SMX-TMP. Attention should be given to PCM-HIV coinfection, emphasizing the concern of a higher risk of PCM therapeutic failure in these patients.
Author Notes
Authors’ addresses: Andreia F. Nery, Department of Infectious Diseases, Julio Müller School Hospital, Federal University of Mato Grosso, Cuiaba, Brazil, and FACIMED, Faculty of Medicine, Cacoal, Brazil, E-mail: andreiafnery@gmail.com. Natasha P. Crepaldi, Department of Dermatology, Julio Müller School Hospital, Federal University of Mato Grosso, Cuiaba, Brazil, E-mail: natashacrepaldi@gmail.com. Soraya B. R. S. Rossi, Department of Infectious Diseases, General University Hospital, Cuiaba, Brazil, E-mail: sorayainfecto@gmail.com. Tomoko Tadano and Rosane Christine Hahn, Faculdade de Ciências Médicas, Universidade Federal de Mato Grosso, Cuiaba, Brazil, E-mails: mokacba@terra.com.br and rchahn@terra.com.br. Fabio A. Leal-Santos, Valfredo M. Menezes, and Cor Jesus F. Fontes, Department of Infectious Diseases, Julio Müller School Hospital, Federal University of Mato Grosso, Cuiaba, Brazil, E-mails: alexandre3025@gmail.com, valmota@gmail.com, and corfontes@gmail.com.